EGFR and non-small cell lung carcinoma: In recent years, the discovery of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has greatly improved the efficacy of patients with advanced NSCLC harboring EGFR mutation (6).